Company: Stealth BioTherapeutics
Job title: Chief Executive Officer
Reenie McCarthy is the Chief Executive Officer and a member of the Board of Stealth BioTherapeutics, a biopharmaceutical company developing investigational therapies to treat mitochondrial dysfunction. Reenie is a 20+ year veteran of the investment team of Morningside, Stealth’s principal investor. Reenie has extensive experience working with numerous private nonclinical and clinical stage companies developing drugs across a broad spectrum of therapeutic areas, both as a Board member and by providing operational and management oversight to venture-backed technology companies. Reenie has been involved with Stealth since 2009, before stepping into a dedicated leadership role at the company in 2015.
Mitochondrial Targeted Therapies & Longevity 3:05 pm
Examine mitochondrial dysfunction and the aging process Explore how mitochondrial-targeted therapeutics can slow, and even reverse age-related decline in animals Discuss how mitochondrial-targeted therapeutics can do the same in humans Consider and evaluate lifespan as a final frontierRead more
day: Day One